高级搜索
CYP2B6 Q172H 和 K262R基因多态性对乳腺癌患者环磷酰胺化疗预后的影响[J]. 肿瘤防治研究, 2010, 37(12): 1387-1390. DOI: 10.3971/j.issn.1000-8578.2010.12.014
引用本文: CYP2B6 Q172H 和 K262R基因多态性对乳腺癌患者环磷酰胺化疗预后的影响[J]. 肿瘤防治研究, 2010, 37(12): 1387-1390. DOI: 10.3971/j.issn.1000-8578.2010.12.014
Prognostic Impact of CYP2B6 Q172H and K262R Polymorphism on Breast Cancer Patients Treated with Cyclophosphamide-based Adjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2010, 37(12): 1387-1390. DOI: 10.3971/j.issn.1000-8578.2010.12.014
Citation: Prognostic Impact of CYP2B6 Q172H and K262R Polymorphism on Breast Cancer Patients Treated with Cyclophosphamide-based Adjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2010, 37(12): 1387-1390. DOI: 10.3971/j.issn.1000-8578.2010.12.014

CYP2B6 Q172H 和 K262R基因多态性对乳腺癌患者环磷酰胺化疗预后的影响

Prognostic Impact of CYP2B6 Q172H and K262R Polymorphism on Breast Cancer Patients Treated with Cyclophosphamide-based Adjuvant Chemotherapy

  • 摘要: 目的 探讨CYP2B6 Q172H和K262R基因多态性与乳腺癌环磷酰胺类药物辅助化疗预后的关系。方法 100例确诊的乳腺癌患者,采用环磷酰胺类药物为主的方案进行辅助化疗;用聚合酶链反应-连接酶检测反应检测CYP2B6 Q172H和K262R基因多态。结果 100例乳腺癌患者中,携带 Q172H(516G>T) GG、GT和TT基因型的患者分别占59%、38%和3%;携带K262R(785A>G) AA、AG和GG基因型的分别占47%、43%和10%。携带Q172H GT和TT基因型的患者无复发生存率显著高于携带GG 基因型的患者(P<0.05);携带K262R AG和GG基因型的患者无复发生存率显著高于携带AA基因型的患者。多因素分析结果显示,Q172H 多态是影响患者复发的独立危险因素(P<0.05)。结论 Q172H GT和TT基因多态与接受环磷酰胺药物辅助化疗的乳腺癌患者的预后有关。

     

    Abstract: Abstract: Objective to study the effect of rotary magnetic field (RMF) combining 5-Fu on the cycle and apoptosis of mouse cell line SP2/0 in vitro. Methods SP2/0 cells were randomly divided into four groups: control group (N), 5-Fu group (C), magnetic group (M) and magnetic combining 5-Fu group (M+C).The M and M+C groups were treated with a RMF for two hours once a day.On day 4, the C and M+C groups were treated with 5-Fu 20 μg/ml.On day 5, cell cycle and apoptosis were measured by the flow cytometric (FCM). Results The S phase proportion of the M group and the G1 phase proportion of the C group were higher than that of the other three groups(P<0.05).The S phase proportion of the M+C group decreased and lower than that of the M group,but was still higher than that of the N and C groups(P<0.05).There was no significant difference in apoptosis rates between the N and M groups(P>0.05).The apoptosis rates of the C and M+C groups were remarkedly higher than those of the N and M groups and the M+C group had the highest apoptosis rate. Conclusion The RMF can't induce the apoptosis.But it can enhance the cytotoxicity of 5-Fu and promote the cell apoptosis.The mechanism of the apoptosis may be related to SP2/0 cell line arrested at S phase.Objective To investigate the association of CYP2B6 Q172H and K262R polymorphisms with clinical outcome of breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy. Methods A total of 100 patients with breast cancer were recruited.All patients received cyclophosphamide-based adjuvant chemotherapy.PCR-LDR (ligation detection reaction) method was used to detect genotypes of CYP2B6 Q172H and K262R. Results Of the 100 patients, the prevalence of the Q172H(516G>T) GG,GT and TT genotype was 59%,38% and 3%, respectively, and the frequencies of K262R(785A>G) AA,AG and GG genotype was 47%,43% and 10%,respectively.The recurrence-free survival rate in patients with Q172H GT and TT genotype were significantly higher than those in patient s with GG genotype (P<0.05).Also, the recurrence-free survival rate in patient s with K262R AG and GG genotype were significantly higher than those in patient s with AA genotype (P<0.05).However, multivariable analysis showed that only Q172H GT and TT genotype were associated with shorter recurrence-free survival (P<0.05). Conclusion Polymorphism of Q172H GT and TT may be a potential prognostic factor in breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy.

     

/

返回文章
返回